Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 6 January 2026 - 18 January 2026

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie shares rose about 0.5% to $221.89 in after-hours trading Wednesday after executives outlined plans to expand into obesity treatments. The company is betting on GUBamy, a drug licensed from Denmark’s Gubra, and highlighted its focus on amylin-based therapies. Investors are watching for pricing pressure from Washington ahead of AbbVie’s Feb. 4 earnings report.
15 January 2026
··
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie shares fell 1.8% to $220.08 Friday after the company cut its Q4 and 2025 profit forecasts, citing a $1.3 billion charge for acquired R&D and milestone expenses. The company denied rumors of takeover talks with Revolution Medicines. AbbVie will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report earnings on Feb. 4.
10 January 2026
···
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie shares fell 1.8% to $220.08 after the company cut its 2025 earnings forecast and denied takeover talks with Revolution Medicines. AbbVie now expects Q4 adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, and full-year EPS of $9.90–$9.94. The company cited $1.265 billion in R&D and milestone charges. AbbVie said its fourth-quarter results are preliminary.
10 January 2026
···
AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie shares fell 0.8% to $222.35 after the company cut its 2025 profit outlook and denied takeover talks with Revolution Medicines. AbbVie now expects fourth-quarter adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, citing a $1.3 billion pre-tax acquired R&D expense. Wolfe Research downgraded the stock to “Peer Perform.” AbbVie said results for the quarter ended Dec. 31 are not yet final.
9 January 2026
··
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie shares fell 4% to $224.13 in after-hours trading Thursday after the company cut its 2025 adjusted profit forecast and disclosed a $1.3 billion acquired R&D charge. The company lowered its full-year 2025 adjusted EPS outlook to $9.90–$9.94 from $10.61–$10.65. AbbVie denied takeover talks with Revolution Medicines. Investors await the company’s Feb. 4 earnings report for further guidance.
9 January 2026
···
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie shares fell 3.7% to $224.84 Thursday after the company denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge tied to R&D and milestone payments. AbbVie trimmed its 2025 profit forecast, setting adjusted earnings at $9.90 to $9.94 per share. Revolution Medicines dropped 5.5%. Wolfe Research downgraded AbbVie, citing limited upside.
8 January 2026
··
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.
8 January 2026
····
1 2 3 4

Stock Market Today

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
ASML stock price snaps back as AI spending bets return, with ex-dividend date next

ASML stock price snaps back as AI spending bets return, with ex-dividend date next

7 February 2026
ASML shares rose 3.84% Friday in Amsterdam to 1,193.80 euros, rebounding with global chip stocks after Amazon signaled a sharp increase in AI-related capital spending. The stock goes ex-dividend Feb. 9 ahead of a 1.60-euro interim payout. ASML’s Nasdaq shares climbed 4.64% to $1,413.01. Despite Friday’s gains, the Amsterdam listing finished the week about 2.5% lower.
Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

7 February 2026
Mastercard shares closed down 0.6% at $548.74 Friday, trailing gains in Visa and American Express. The Dow Jones Industrial Average surged 2.47% to a record 50,115.67. Mastercard disclosed a new cybersecurity partnership in the UAE and raised compensation for two top executives. U.S. jobs and inflation data, delayed by a government shutdown, are due next week.
Go toTop